Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. (BTCY) delivers innovative medical technology solutions focused on AI-powered cardiac monitoring and chronic disease management. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in remote patient care.
Access timely press releases covering regulatory milestones, clinical study results, and strategic partnerships with healthcare institutions. Stay informed about product developments like the Bioflux cardiac monitoring system and consumer-focused Biolife platform, which combine medical-grade accuracy with AI-driven analytics.
Our curated news collection features earnings reports, technology patent announcements, and market expansion updates. Bookmark this page for verified information about BTCY’s progress in transforming cardiac care through connected health solutions.
Biotricity (OTCQB: BTCY) has been named one of the Americas' Fastest-Growing Companies 2025 by the Financial Times, achieving remarkable growth of 256.4% between 2020 and 2023. The company, specializing in Technology-as-a-Service for diagnostic and chronic disease management solutions, has demonstrated exceptional performance despite global challenges including the COVID-19 pandemic and supply chain disruptions.
The recognition comes as Biotricity addresses a critical healthcare gap, with over 100 million Americans facing barriers to accessing essential healthcare services. The company's proprietary remote monitoring technologies have particularly impacted high-risk cardiac patients, enabling medical providers to deliver faster interventions both in the U.S. and internationally.
The complete Financial Times report will be published on April 25, 2025, available to U.S. newspaper subscribers and globally on ft.com.
Biotricity (OTCQB:BTCY) has significantly expanded its intellectual property portfolio with 14 new patents, bringing its total to 15 issued patents and 14 pending. The company's latest innovations focus on a breakthrough multi-biometric device platform that can function as both a patch and watch for remote patient monitoring.
The new technology enables simultaneous diagnostic studies through a versatile device with base components that can be transferred between patch and watch form factors. This advancement allows for concurrent diagnostic assessments, such as cardiac and sleep studies, streamlining the patient care process and reducing diagnosis delays.
The expanded patent portfolio reinforces Biotricity's position in remote monitoring, diagnostics, and chronic disease management solutions. The company's Technology-as-a-Service (TaaS) approach aims to improve patient outcomes by enabling earlier detection of health issues while generating revenue through insurance reimbursement.
Biotricity (BTCY) reported strong Q3 FY25 results with revenue growth of 21.7% YOY to $3.6 million. The company achieved significant improvements in key metrics, including gross margins reaching 76.4% (up from 72.9% YOY) and a 56.7% reduction in net loss to $1.32 million.
Recurring Technology Fee revenue, comprising 94% of total revenue, demonstrated robust performance with an 81.4% gross profit percentage. The company successfully reduced SG&A expenses by 20.5% to $2.38 million compared to the previous year. Biotricity achieved positive cash flow on current operating basis for the second consecutive quarter, showing a 114.5% improvement from the prior quarter.
The company's technology is currently utilized across hundreds of centers in 35 states, with a growing focus on hospital networks and AI-driven solutions for remote cardiac care.
Biotricity (OTCQB: BTCY), a Technology-as-a-Service company in remote cardiac monitoring, has announced strong financial performance for Q3-FY25. The company expects to report revenue of $3.6 million, representing a 22% year-over-year growth and an 11% sequential increase from the previous quarter.
The company will achieve positive cash flow for Q3-FY25 on current operating basis (before interest, dividends, and amortization), along with improved gross margins and operating results. This progress stems from their focus on automation, operating efficiency, and financial discipline while leveraging their Biocore suite of products and AI-driven solutions.
The full financial results will be released on February 19th, 2025, followed by a conference call on February 20th at 5:30 PM EST.
Biotricity Inc. (OTCQB:BTCY) and B-Secur have announced a strategic partnership to develop an advanced device-neutral platform for integrated heart monitoring. The collaboration combines B-Secur's FDA-cleared HeartKey® algorithms and analytics with Biotricity's diagnostic solutions to enhance Ambulatory Cardiac Monitoring capabilities.
The partnership aims to address critical healthcare challenges, including the fact that 90% of U.S. adults are at risk of developing cardiovascular disease (CVD), an expected shortage of up to 124,000 physicians by 2034, and CVD-related costs projected to triple to $1.8 trillion by 2050. The solution focuses on early detection and intervention, which can reduce heart attack and stroke risk by over 80%.
Biotricity (OTCQB: BTCY) has secured significant financing to strengthen its financial position and reach profitability without requiring future funding. The company completed an $811,000 capital raise through promissory notes, matched with a $635,000 term loan. The lender also provided interest relief by capitalizing $945,000 in existing debt.
This capital enabled Biotricity to place its largest manufacturing order to date, preparing for anticipated 2025 sales. The company's AI workflow engine has improved operational capacity by 50%, with an additional 15% improvement expected. Their next-generation AI cloud system is projected to reduce COGS across their SaaS business by 5% post-FDA clearance.
Biotricity (OTCQB: BTCY) has achieved positive free cash flow for the first time, marking a significant milestone towards profitability. For the quarter ended September 30, 2024, the company reported positive Free Cash Flow of $355,016 ($0.016 per share), a substantial improvement from negative $725,567 in the previous quarter and negative $1.6 million in the same quarter last year. This achievement demonstrates the company's progress in operational efficiency and financial discipline. Management plans to accelerate new product launches in FY25 to enhance long-term profitability and sustainability.
Biotricity (BTCY) reported Q2 FY25 financial results with 13% year-over-year revenue growth to $3.3 million. The company achieved significant improvements in key metrics, including gross margins increasing to 75.3% from 69.1% year-over-year. Recurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentage. The company reduced SG&A by 35.5% to $2.25 million and decreased net loss by 57.4% to $1.65 million. Notably, Biotricity achieved positive cash flow in September on a current operating basis, before interest, dividends, and amortization, with management expecting continued improvement in cash flows.
Biotricity (OTCQB:BTCY) has scheduled its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call for November 15, 2024, at 4:30 PM ET. The company announces its best financial performance to date, highlighting improvements in margins, operational efficiency, and a shift to positive adjusted EBITDA. The call will feature CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou, followed by an investor Q&A session. A replay will be available for approximately 3 hours after the live call through November 29, 2024.
Biotricity Inc. (OTCQB:BTCY), a Technology-as-a-Service company in the healthcare industry, has announced an accelerated path to profitability by the end of Fiscal Q4. The company reports growing revenues from sales and strategic partnerships, improving margins, and has achieved EBITDA positive on a go-forward cash basis earlier than expected.
CEO Dr. Waqaas Al-Siddiq attributes this success to the company's novel approach and increasing demand for their diagnostically superior remote monitoring solutions. Biotricity's flagship product, Biocore Pro, is highlighted as the only 3 channel connected cardiac monitor in the world. The company aims to leverage its technology suite to address gaps in care delivery for both medical providers and patients.
